Updates to the Australian Pharmaceutical Benefits Scheme

Services Australia has published a release detailing new and amended listings of medications on the Australian Pharmaceutical Benefits Scheme (PBS), effective from 1 May 2023.

Amendments have been made to a range of medications on the PBS, including the following medications:

• Methylphenidate (Ritalin® LA) being amended to allow access for adults with a retrospective diagnosis of ADHD. This includes access to capsules containing methylphenidate hydrochloride 10 mg, 20 mg, 30 mg, 40 mg, 60mg (modified release).
• Naltrexone (Naltrexone GH®) having a reduction in authority level for the treatment of alcohol dependence.

Enquiries regarding new and amended listings can be directed to the PBS at pbs@health.gov.au.